Multiple Myeloma Over Two Decades:Where Do We Go from Here?
10.13865/j.cnki.cjbmb.2025.06.1274
- VernacularTitle:多发性骨髓瘤二十年:未来路在何方?
- Author:
Zhi-Qiang LIU
1
Author Information
1. 山东省肿瘤精准防治重点实验室,山东省肿瘤医院,山东第一医科大学,济南 250117
- Publication Type:Journal Article
- Keywords:
multiple myeloma;
guideline;
expert consensus;
immunotherapy
- From:
Chinese Journal of Biochemistry and Molecular Biology
2025;41(6):771-773
- CountryChina
- Language:Chinese
-
Abstract:
Multiple myeloma(MM)is the second most common hematological malignancy,predominant-ly affecting the elderly.With the development of an aging society in China,the incidence of MM has been steadily increasing,becoming a significant concern for public health and a considerable socioeco-nomic burden.Over the past two decades,breakthroughs have been achieved in both clinical manage-ment and basic research on MM.However,the field now stands at a crossroads for the next phase,facing numerous developmental directions and challenges.
